We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-3.00 | -9.84% | 27.50 | 27.00 | 28.00 | 30.50 | 27.50 | 30.50 | 1,295,607 | 10:16:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -3.19M | -0.0469 | -5.97 | 19.06M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/5/2022 20:51 | What does the UEFA Champions League have to do with immune based therapies? 😜 | norma_stitts | |
28/5/2022 17:54 | Just watched a segment on GB news re UCL and immune based therapies. Looking at monies raised due to Prof Janet Thornton and fighting cancer. Found this RNS extract from Sareum 2005 of which we were involved! Inpharmatica’s initial technology was based on research from Professor Janet Thornton’s group at University College London. The Company employs approximately 100 professionals at its UK locations in London and Cambridge, with business development headed in North America. Inpharmatica has raised some £35.0m from leading venture capitalists and has sales/collaboration partnerships with Serono, Pfizer, GSK, Aventis, Daiichi, Riken, Taisho, UCB Pharma, MDL, Ionix, CellZome and Galapagos. Seems to me a lot of big names are dovetailing re immunotherapy treatment and Sareum are definitely part of the group albeit not being named. Tyk tok. Regards CT | criticalthinker1 | |
28/5/2022 09:06 | Well basically all I understand us MPG and that fuel costs too much we shall see what it looks like after 10 days running round up here although it's mostly country lane driving.Critical the share price does what it likes can't say I am a great believer in it being manipulated all the time. Sometimes maybe when a big buy is going through but I don't believe all these figures that go through and deffo not the colour of trades. The warrant issue is intriguing but could that be for introducing the HNWIs to us and them having stayed with us. You could be right in that they have been setting something else up as well.As for TR1 issue different rules apply in different countries and I think they differ by ordinary PI and II investment.Nobody has explained to me why none appeared in the week a billion shares in SAR traded two years ago. | silvergreyhead1 | |
27/5/2022 21:39 | It's why I had squeaky bum time when petrol shortage was on. Car can only run on 99 octane. | madd_rip | |
27/5/2022 19:11 | Hi Silver. Have a great getaway. Word of advice re fuel. Don't use E10 in your vehicle or garden machinery. Because its 10% ethanol it draws moisture and affects o rings etc that are plastic based which then degrade. Second point. What's your opinion on the share price staying stagnant yet the buys are extremely superior? Do you think PH are buying what they can and filling iis fill orders. Surely given the time this has been going on a TR1 is incoming given just over 2m shares required. Makes me think about some holders who claim to hold certain large volumes yet have not been mentioned in a TR1! Maybe the 29m share option 'thanks' to 'introducers' which can be purchased when share price hits x but post consolidation equates to 580k, Something is happening. Those continued buys before would have seen a significant share price rise. I'm waiting for the big bang. Q3? ;-) ? Anyhows have a great holiday. CT | criticalthinker1 | |
27/5/2022 18:33 | Here's a boring one for youOld E5 petrol used to get 46 mpg combinedNew E10 petrol absolutely sh.t down to 40 mpg com.Super E5 petrol 48 mpg com. so started using that okay it was around 5% more but got 20% better mileage than E10 sh.tSo this week did a halfy halfy filled half with E5 and half with E10 two different garages so as not to look a Pillock. About to refill tomorrow and running at 52 mpg. Slightly more Mway in this time but Louise does that driving and if she's below 75 mph the are in roadworks or volume.So if Critical can write sh.te we all can. Have a great weekend folks I am up in sunny Belford for ten days on the beer and the beaches( Only playing critical keep posting mate ) | silvergreyhead1 | |
27/5/2022 12:19 | No - my mates know me as Johann Wolfgang von Goethe, you can call me Barkers. lol | barkbooo | |
27/5/2022 12:17 | are you Rebecca Vardy ? | horridhenry | |
27/5/2022 11:37 | horridhenry - I am more innocent until proven guilty kinda guy...but you can never be too careful. If you thought this thread had rags - the vetting necessary on our TRMR thread is like a week at the Old Bailey! | barkbooo | |
27/5/2022 10:05 | Silver he's a frog kisser. He is much better off on LSE where there are loads of them | horridhenry | |
26/5/2022 21:37 | Also just an additional point. GSK advised they needed to appoint more directors with scientific backgrounds. Now where did we here one of our board say discussions recently with 'x' say that discussions were held but further discussions were required at a later date. Wink wink. Best regards CT | criticalthinker1 | |
26/5/2022 21:17 | Thankyou Norma. Just thought we might have had an update re flt3 data as Sareum BOD advised. Anyhow this re GSK turning down Nestle £50billion offer ( with what could of been Reckitt being involved) Quite interesting re "pipeline" Haleon is an attractive consumer asset, which should ultimately be reflected in its independent valuation,” analysts at Jefferies Financial Group Inc. wrote in a note Thursday, citing the potential takeover interest. The report “suggests̶ The report today also advises that Elliot is keen on getting pipeline drugs into GSK ownership. Something is brewing for Sareum I'm convinced. Regards CT | criticalthinker1 | |
26/5/2022 17:24 | Barkboo voted for him last time to get Brexit done. Without getting into any political or behavioural arguments for me his and Sunaks time is well gone now.Vote Super Frankie Lampard from now!And of course that is with the greatest respect to yours and everyone's opinions on here, don't want Horrid getting on at me. | silvergreyhead1 | |
26/5/2022 16:34 | Silver - I like Boris..he plays the remoaner idiots in our press to perfection. They think they are beating him, look at his political career - he never loses, and never shouts about that. lol Silver I respect your views whatever. | barkbooo | |
26/5/2022 16:17 | Just wish SAR would realise it's true value soon. Then I can tell Sunak Boris and the likes to just f.ck off | silvergreyhead1 | |
25/5/2022 21:14 | Criticalthinker1, It was never announced who the Chinese pharma was. Was handed back as they couldn’t resolve solubility issues along with extra data. IIRC they only paid £50k upfront, which for me, was indicative that they didn’t hold high hopes of resolving it. | norma_stitts | |
25/5/2022 20:47 | Also this re FLT3 26th March 2020 RNS Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that it has entered into an agreement (the “AgreementR Anybody know who the specialist pharma company is? There's a storm brewing if you read more than msm. If our BOD say they have the research and we're going to investigate flt3 why have we heard nothing. And don't say they don't have funds! | criticalthinker1 | |
25/5/2022 19:34 | Hi silver. But given the addition and then departing of kowalski at SO (forgot his correct name) which Sareum in a RNS stated they were very happy with regards to his acknowledgement of pipeline drugs at SO. I'm wondering if 737 has had a bit more attention than we know. Interesting times. Also if they bought 737 solely as a drug from CRUK and Sareum via SO would that not get the jungle drums beating!? Just seeing the trades at Sareum for about 6 weeks I'm convinced the newly introduced corporate advisors are keeping a lid on the share price Will it be to benefit the iis via shareholders getting bored and selling? Something is happening. The trades and spread and share price speaks volumes of market control due to incoming news. My opinion CT | criticalthinker1 | |
25/5/2022 18:28 | Hello Critical the GSK buying Sierra to secretly get 737 theory is rife on LSE. Personally don't buy it if they wanted 737 to they could have bought it on its own for a lot less. My hope is the CPR are onto GSK as soon as the TO is finalised as to their intention in regards to 737. Probably not they are a charity and can continue on without cash from 737 SAR are a business and could do with 737 progressing to a revenue stream. 737 if all reports are true could help a lot of pigging people get some relief from this awful disease.I do see some sense in the argument that GSK may sell on 737 to another big pharma, apparently one has removed references to 737 from it's website, conspiracy or what? | silvergreyhead1 | |
25/5/2022 17:28 | So this extract from GSK RNS 13th April 2022 re potential T/O of SO. Note they talk about Mom but don't hide the other main two pipeline drugs. About Sierra Oncology Sierra Oncology is a late-stage biopharmaceutical company based in San Mateo, California, on a mission to deliver targeted therapies that treat rare forms of cancer. In addition to momelotinib, the pipeline consists of two assets in phase I SRA515 and SRA737. SRA515 is a selective bromodomain-containi Just wondering if the new appointment re AI is to get 737 a fanfare at some point. Best regards CT | criticalthinker1 | |
25/5/2022 17:17 | Greatly appreciate your response silver. Like to add this re GSK and SRA737 4th May 2022 re new appointment and how they might be using his expertise to fast track pipeline drugs Vishal has a distinguished background in technology and particularly in the field of Artificial Intelligence (AI) and Machine Learning, which is central to GSK's approach to R&D Going to add what GSK said re SRA 737 re the SO potential T/O | criticalthinker1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions